Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | RPA1 | P27694 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21935300 | 0.88 | PTGS2 (0.60) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL14747805 | 0.87 | PTGS2 (0.74) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL4247328 | 0.87 | PTGS2 (0.74) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL21935294 | 0.85 | KLKB1 (0.53) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL21879588 | 0.84 | KLKB1 (0.62) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL31420334 | 0.84 | KLKB1 (0.62) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL6451398 | 0.83 | PTGS1 (1.00) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL21879532 | 0.82 | KLKB1 (0.52) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL20502210 | 0.82 | KDM4E (0.56) | PTGS1MAPTSMN1; SMN2TP53PTGS2 | |
| SCHEMBL21935232 | 0.82 | PTGS2 (0.61) | PTGS1MAPTSMN1; SMN2TP53PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| EP-3596067-B1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2020-04-30 | — | — | US | disclosed |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | PTGS1 2381/4885MAPT 4663/4885SMN1; SMN2 4800/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | PTGS1 2381/4885MAPT 4663/4885SMN1; SMN2 4800/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | PTGS1 2397/4885MAPT 4662/4885SMN1; SMN2 4793/4885 |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC3 | PTGS1 2397/4885MAPT 4662/4885SMN1; SMN2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.